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2526Shield of Michigan Cardiovas-
cular Consortium Peripheral Vas-
cular Intervention (BMC2 PVI)
registry is a statewide, multihospital,
physician-coordinated, quality-
improvement initiative focused
on all patients undergoing per-
cutaneous peripheral vascular
interventions (PVIs). Data from
this real-life cohort of patients
were utilized to evaluate pro-
cedural outcomes by sex.
Methods
The study population consisted
of consecutive patients who un-derwent PVI between January 1, 2004, and December 31,
2009, at 16 hospitals in Michigan. Details regarding BMC2
PVI have been described elsewhere (11). Data were col-
lected on demographic and clinical characteristics of patients
undergoing PVI procedures. Approval from institutionalBaseline Characteristics for PVI Patients
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ic obstructive pulmonary disease; eGFR ¼ estimated glomerureview boards was obtained for each center. All patients
who underwent lower extremity (LE) PVI, deﬁned as an
endovascular intervention performed on an artery in the
aortoiliac, femoropopliteal, and below the knee arterial
beds, were included in this analysis. Major endpoints for
this analysis included in-hospital death, myocardial infarc-
tion (MI), stroke or transient ischemic attack (TIA), and
in-hospital major adverse cardiovascular events, deﬁned as
the composite of death, MI, and stroke/TIA. Intra-
procedural endpoints included embolic or thrombotic
complications. Post-procedural endpoints included repeat
PVI, post-PVI amputation, post-procedural transfusions
of red blood cells, and vascular access complications. Pro-
cedural variables included technical success, deﬁned as vas-
cular access, deployment of device(s), and 30% diameter
residual stenosis after revascularization; and procedural
success, deﬁned as technical success and freedom from
major peri-procedural complications (12). Further details of
the registry and the analysis are provided in the Online
Appendix.
Statistical analysis. The differences in discrete variables
between groups were evaluated by the chi-square test anden Men
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2527Fisher exact test, and continuous variables by the Student’s
t-test and Wilcoxon rank sum test. We used propensity
matching to compare the adjusted outcome of women and
men. The probability or a propensity score of being a woman
if all other baseline variables were known was calculated
using a nonparsimonious logistic regression model. SAS
version 9.3 software (SAS Institute, Cary, North Carolina)
was used for all analyses.
Results
A total of 12,379 patients were included in this analysis, of
which 41.2% were women (Table 1). Female LE-PVI pa-
tients were more likely to be older and to have a history of
hypertension compared with male PVI patients. Women
were less likely to be overweight or obese, be current
smokers, or have a medical history for coronary artery disease
or hyperlipidemia compared with men. The indications for
LE-PVIs differed between men and women. Men were
more likely to have claudication symptoms, whereas women
were more likely to present with critical limb ischemia (CLI)
as an indication for PVI (Table 1).
Sex-related differences were also observed for LE-PVI
location and procedure characteristics (Table 2). Women
were more likely to undergo interventions in the femo-
ropopliteal location and were more likely to have multilevel
disease, thus requiring multilevel intervention (deﬁned as 2
or more arterial beds; i.e., aortoiliac bed, femoropoplitealTable 2 PVI Location, Access Type, Device Usag
Procedure Characteristics
Intervention location
Aortoiliac
Femoropopliteal
Below knee (tibial, peroneal, dorsalis pedis, or tibioperoneal
trunk
Multivessel interventions (2 or more arterial bed)
Access type
Antegrade intervention*
Retrograde intervention
Antegrade and retrogradey
Device
Balloon only
Stent
Any atherectomy
IVUS
Cutting balloon
Cryoballoon
Laser
Thrombolysis
Closure device
Manual
Closure device (Perclose, Angio-Seal, or VasoSeal)
Values are n (%). *Antegrade/retrograde information was available only for
were used.
IVUS ¼ intravascular ultrasound; PVI ¼ peripheral vascular intervention.bed, below the knee). Mode of intervention also differed on
the basis of sex, with more female patients undergoing PVI
with balloon only or atherectomy with balloon, whereas
more male patients received interventions using stents. Male
access site vessels were less likely to be closed using a closure
device, whereas female patients were more likely to receive a
closure device.
Female patients were less likely to receive several cardio-
vascular medications before PVI as compared with male
patients, including angiotensin-converting enzyme (ACE)
inhibitors, and lipid-lowering medications including statins
(Table 3). Fewer women received dual antiplatelet therapy.
Receipt of any antiplatelet therapy before the procedure
was lower among women compared with men. After PVI,
rates of receipt of ACE inhibitors and lipid-lowering med-
ications (including statins) continued to be lower for women
compared with men.
In unadjusted analysis, no sex-related differences were
observed for in-hospital death, MI, stroke/TIA, or ampu-
tation (Table 4). Women experienced higher rates of
unadjusted post-procedure transfusion, vascular access com-
plications, and repeat PVI compared with male patients.
Technical success was achieved less often among men
compared with women. Procedural success was observed more
often among men compared with women.
In a propensity-matched analysis, 2,346 women were
matched to an equal number of men (Table 4). Compared
with male patients, women experienced more transfusions,e, and Procedural Success in Women and Men
Women Men
p Valuen ¼ 5,105 (41.2%) n ¼ 7,274 (58.8%)
1,608 (31.5) 2,310 (31.7) 0.7
3,513 (68.9) 4,828 (66.4) 0.004
1,292 (25.3) 1,860 (25.6) 0.7
2,661 (52.2) 3,602 (49.5) 0.004
410 (10.5) 624 (11.5) 0.1
3,423 (87.5) 4,660 (85.9) 0.03
79 (2.0) 139 (2.5) 0.08
1,649 (32.3) 2,165 (29.7) 0.002
2,081 (40.7) 3,117 (42.8) 0.02
1,174 (23.0) 1,551 (21.3) 0.02
170 (3.3) 231 (3.2) 0.6
150 (2.94) 233 (3.2) 0.4
284 (5.56) 377 (5.18) 0.3
331 (6.48) 526 (7.23) 0.1
78 (1.53) 118 (1.62) 0.6
2,217 (55) 3,209 (57.3) 0.02
1,814 (45.0) 2,391 (42.7) 0.02
9,335 cases of 12,379. yBoth antegrade and retrograde access types
Table 3 Pre- and Post-Procedural (Discharge) Medication Usage Between Sexes
Characteristics
Women Men
p Valuen ¼ 5,105 (41.2%) n ¼ 7,274 (58.8%)
Pre-procedural medication
ACE inhibitor 2,210 (45.7) 3,538 (51.2) <0.0001
Beta-blocker 3,077 (62.2) 4,467 (63.3) 0.2
Statin 3,394 (67.7) 5,155 (71.8) <0.0001
Any lipid lowering* 3,578 (71.3) 5,414 (75.5) <0.0001
Mono-antiplatelety 1,839 (36.0) 2,558 (35.2) 0.3
Dual antiplateletz 2,326 (45.5) 3,470 (47.7) 0.02
Any antiplateletx 4,346 (85.1) 6,337 (87.1) 0.001
Coumadin 319 (6.2) 514 (7.1) 0.07
Heparin 325 (6.4) 382 (5.2) 0.008
Discharge medication
ACE inhibitor 2,338 (48.6) 3,657 (53.2) <0.0001
Beta-blocker 3,249 (66.0) 4,745 (67.5) 0.09
Statin 3,722 (74.6) 5,504 (77.0) 0.002
Any lipid lowering 3,885 (77.9) 5,738 (80.3) 0.001
Mono-antiplatelet 974 (19.1) 1,201 (16.5) 0.002
Dual antiplatelet 3,557 (69.7) 5,167 (71.0) 0.1
Any antiplatelet 4,812 (94.8) 6,877 (94.9) 0.8
Coumadin 560 (11.0) 883 (12.1) 0.04
Heparin 359 (7.0) 437 (6.0) 0.02
Values are n (%) unless otherwise speciﬁed. *Any lipid lowering indicates a choice of any lipid-lowering agents. yMono antiplatelet indicates a choice
of any one antiplatelet agent from aspirin, clopidogrel, ticlopidine, or cilostazol. zDual antiplatelet indicates a choice of any 2 antiplatelet agents from
aspirin, clopidogrel, ticlopidine, or cilostazol. xAny antiplatelet indicates a choice of any antiplatelet from aspirin, clopidogrel, ticlopidine, or cilostazol.
ACE ¼ angiotensin-converting enzyme.
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2528vascular complications, and embolic or thrombotic compli-
cations. Women were more likely to have technically suc-
cessful PVIs compared with men. Overall procedural
success, which combines technical success with adverse
events such as vascular complications or bleeding events, was
similar among women and men.Table 4 Propensity-Matched In-hospital Adverse Events in Female an
In-Hospital Outcomes
Matched Data*
Women
(n ¼ 2,346)
Men
(n ¼ 2,346)
Death 9 (0.38) 5 (0.21)
MI 14 (0.6) 7 (0.3)
TIA/stroke 5 (0.2) 5 (0.2)
MACE 22 (0.9) 14 (0.6)
Transfusion 164 (6.99) 89 (3.79)
Vascular access complications 105 (4.48) 47 (2.00)
Embolic complications 27 (1.15) 10 (0.43)
Thrombotic complications 17 (0.72) 21 (0.9)
Amputation 103 (2.0) 134 (1.84)
Lesions not crossed 64 (2.73) 87 (3.71)
Technical success 2,140 (91.22) 2,090 (89.09)
Procedural success 1,870 (79.7) 1,916 (81.67)
Length of hospital stay, days
Mean  SD 1.92  3.6 1.69  3.19
Median (Q1, Q3) 1 (1, 1) 1 (1, 1)
Values are n (%) unless otherwise speciﬁed. *Patient characteristic variables that were used for match
hyperlipidemia, congestive heart failure, chronic obstructive pulmonary disease, anemia, body mass inde
(aortoiliac, femoropopliteal, and below knee), and pre-procedural medication usage (angiotensinogen inhi
tiroﬁban, lipid-lowering drug, antiplatelet therapy).
MACE ¼major adverse cardiovascular event(s); MI ¼myocardial infarction; PVI ¼ peripheral vascular inDiscussion
In this large cohort of patients undergoing LE-PVI, we
observed that women presented with more severe manifes-
tations of PAD and had more complications, but had similar
rates of procedural success and were more likely to haved Male PVI Patients
All Data
p Value
Women
(n ¼ 5,105)
Men
(n ¼ 7,274) p Value
0.3 31 (0.6) 28 (0.4) 0.08
0.2 32 (0.6) 35 (0.48) 0.3
1.0 11 (0.22) 14 (0.2) 0.8
0.2 63 (1.2) 65 (0.9) 0.06
<0.0001 429 (8.4) 309 (4.2) <0.0001
<0.0001 248 (4.9) 152 (2.1) <0.0001
0.005 40 (0.8) 24 (0.3) 0.0005
0.5 52 (1.0) 49 (0.7) 0.04
0.4 47 (2.0) 42 (1.8) 0.6
0.057 302 (5.9) 587 (8.07) <0.0001
0.014 3,993 (86.9) 5,578 (84.5) 0.0004
0.08 3,456 (75.2) 5,107 (77.4) 0.008
2.15  3.98 1.76  3.37
<0.0001 1 (1, 1) 1 (1, 1) <0.0001
ing are age, estimated glomerular ﬁltration rate, coronary artery disease, diabetes, hypertension,
x categories (lean, overweight and obese), claudication, critical limb ischemia, vascular bed location
bitors, b-blockers, heparin, low molecular weight heparin, warfarin, diuretic, bivalirudin, eptiﬁbatide/
tervention; TIA ¼ transient ischemic attack.
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2529technical success associated with PVI compared with male
patients.
Factors associated with PAD and PVI. As with prior
studies (13–15), we observed that women were generally
older and less likely to smoke, but more likely to have a prior
history of hypertension. We also observed that women more
often presented with CLI. Given that men were more likely
to be smokers and have elevated lipids, the etiology for
women having a more severe presentation of CLI is unclear.
Other investigators have suggested that comorbidities
including osteoporosis and arthritis may confound tradi-
tional assessments of claudication in women (15,16).
Furthermore, women may present late with PAD and thus
be more likely to present with CLI.
Difference in medications. We observed similar rates of
receipt for most cardiac medications with the exception of
ACE inhibitors and statin therapy. Receipt of statins on
discharge increased from pre-procedure rates for both sexes;
however, 23% of men and 25.4% of women were still not
receiving statins at the time of discharge. Given that PAD
is considered as a coronary artery disease risk equivalent,
our ﬁndings suggest room for improvement with regard to
compliance with current medical therapy guidelines (17,18).
In-hospital post-procedural outcomes. We observed no
sex-related differences for in-hospital death, MI, stroke/
TIA, or the combined endpoint of these outcomes. We did,
however, observe increased vascular complications and post-
procedural transfusions among women as compared with
men. The ﬁndings regarding an increased risk of vascular
access complications, bleeding, and transfusions among fe-
male patients who undergo PVI procedures are consistent
with other studies (13,19). A review of hospital discharge
databases from New York, New Jersey, and Florida de-
monstrated increased risk of bleeding after vascular in-
terventions for PAD for women compared with men. In
that study, women also had higher peri-operative mortality
rates; however, procedures were not limited to PVIs and
thus included open procedures and amputations (13).
We also observed that women were more likely to receive
pre-PVI procedure heparin as compared with men. This
is likely related to the higher proportion of women who
presented with CLI; however, the use of pre-procedural
heparin may be a factor in the increased bleeding observed
among women (20). The increase in vascular and bleeding
complications mirrors what has been observed in sex-speciﬁc
data on coronary interventions (7,21).
Given the higher rates of PVI-related vascular access
complications and transfusions among female patients as
compared with male patients, it was surprising to observe
no sex-related difference in procedural success, a clinically
meaningful measure of technical success and freedom from
complications. This paradox was explained by the observed
higher rates of technical success for women as compared
with men. These data suggest female patients may beneﬁt to
a greater degree with an invasive percutaneous strategy for
the management of PAD, particularly if complicationscan be avoided. The data in our study are not from a ran-
domized controlled trial; clearly further research regarding
sex-related differences in the technical and procedural suc-
cess of PVI is warranted.
Study limitations. Several limitations exist for this study.
First, the ﬁndings represented here are based on observa-
tional data that are not adjudicated by a core facility; as
such it may be limited by variability in measurement.
However, adverse outcomes are audited by the BMC2 PVI
coordinating center staff for completeness and accuracy.
Second, data were examined using risk-adjustment models
and propensity analysis; however, we cannot exclude
possible residual confounding by known and/or unknown
factors. Third, all patients in our study underwent PVI at
hospitals participating in a quality-improvement initiative
(22). The ﬁndings may or may not apply to other in-
stitutions or to patients from other geographically distinct
areas.Conclusions
In this real-world registry, we observed that women
had inferior adherence to guideline-recommended medical
therapy before the procedure and, although improved, were
less likely to receive statins than men post-PVI. Paradoxi-
cally, female sex was associated with superior technical
success but more procedural complications that resulted in
similar rates of procedural success associated with LE-PVI.
These data suggest the need for quality-improvement in-
terventions designed to improve medical therapy and en-
hanced efforts to understand and ameliorate PVI-associated
complications, in particular bleeding and vascular complica-
tions among women.
Reprint requests and correspondence: Dr. P. Michael Grossman,
Cardiovascular Medicine, University of Michigan, 1500 East
Medical Center Drive, 2A596 CVC, Ann Arbor, Michigan
48109-5869. E-mail: pagross@umich.edu.REFERENCES
1. Allison MA, Ho E, Denenberg JO, et al. Ethnic-speciﬁc prevalence of
peripheral arterial disease in the United States. Am J Prev Med 2007;
32:328–33.
2. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence
of peripheral arterial disease and risk factors in persons aged 60 and
older: data from the National Health and Nutrition Examination
Survey 1999–2004. J Am Geriatr Soc 2007;55:583–9.
3. Go AS, Mozaffarian D, Roger VL, et al., American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Executive
summary: heart disease and stroke statisticsd2013 update: a report
from the American Heart Association. Circulation 2013;127:143–52.
4. Vaccarino V, Rathore SS, Wenger NK, et al., National Registry of
Myocardial Infarction Investigators. Sex and racial differences in the
management of acute myocardial infarction, 1994 through 2002.
N Engl J Med 2005;353:671–82.
5. Argulian E, Patel AD, Abramson JL, et al. Gender differences
in short-term cardiovascular outcomes after percutaneous coronary
interventions. Am J Cardiol 2006;98:48–53.
Jackson et al. JACC Vol. 63, No. 23, 2014
Sex-Related Outcomes for PAD Intervention June 17, 2014:2525–30
25306. Mehilli J, Kastrati A, Dirschinger J, et al. Sex-based analysis of
outcome in patients with acute myocardial infarction treated predom-
inantly with percutaneous coronary intervention. JAMA 2002;287:
210–5.
7. Jackson EA, Moscucci M, Smith DE, et al. The association of sex with
outcomes among patients undergoing primary percutaneous coronary
intervention for ST elevation myocardial infarction in the contemporary
era: insights from the Blue Cross Blue Shield of Michigan Cardio-
vascular Consortium (BMC2). Am Heart J 2011;161:106–112.e101.
8. Champney KP, Frederick PD, Bueno H, et al., NRMI Investigators.
The joint contribution of sex, age and type of myocardial infarction on
hospital mortality following acute myocardial infarction. Heart 2009;
95:895–9.
9. Berger JS, Elliott L, Gallup D, et al. Sex differences in mortality
following acute coronary syndromes. JAMA 2009;302:874–82.
10. Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW,
Chan L. Treatment of acute myocardial infarction and 30-day mortality
among women and men. N Engl J Med 2000;343:8–15.
11. Mukherjee D, Munir K, Hirsch AT, et al. Development of a multi-
center peripheral arterial interventional database: the PVD-QI2. Am
Heart J 2005;149:1003–8.
12. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting
standards in studies assessing endovascular treatment for chronic
ischaemia of lower limb arteries. Eur Heart J 2007;28:798–805.
13. Vouyouka AG, Egorova NN, Salloum A, et al. Lessons learned from
the analysis of gender effect on risk factors and procedural outcomes of
lower extremity arterial disease. J Vasc Surg 2010;52:1196–202.
14. Abando A, Akopian G, Katz SG. Patient sex and success of peripheral
percutaneous transluminal arterial angioplasty. Arch Surg 2005;140:
757–61.
15. Vouyouka AG, Kent KC. Arterial vascular disease in women. J Vasc
Surg 2007;46:1295–302.
16. McDermott MM, Ferrucci L, Liu K, et al. Women with peripheral
arterial disease experience faster functional decline than men with
peripheral arterial disease. J Am Coll Cardiol 2011;57:707–14.
17. Grundy SM, Cleeman JI, Merz CN, et al., National Heart, Lung, and
Blood Institute; American College of Cardiology Foundation; Amer-
ican Heart Association. Implications of recent clinical trials for the
National Cholesterol Education Program Adult Treatment Panel III
guidelines. Circulation 2004;110:227–39.18. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines
for the management of patients with peripheral arterial disease (lower
extremity, renal, mesenteric, and abdominal aortic): executive summary
a collaborative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovascular
Angiography and Interventions, Society for Vascular Medicine and
Biology, Society of Interventional Radiology, and the ACC/AHA Task
Force on Practice Guidelines (Writing Committee to Develop
Guidelines for the Management of Patients With Peripheral Arterial
Disease) endorsed by the American Association of Cardiovascular and
Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute;
Society for Vascular Nursing; TransAtlantic Inter-Society Consensus;
and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:
1239–312.
19. Kawamura A, Piemonte TC, Nesto RW, Bilazarian SD, Riskalla NS,
Chauhan MS. Impact of gender on in-hospital outcomes following
contemporary percutaneous intervention for peripheral arterial disease.
J Invasive Cardiol 2005;17:433–6.
20. Kasapis C, Gurm HS, Chetcuti SJ, et al. Deﬁning the optimal degree
of heparin anticoagulation for peripheral vascular interventions: insight
from a large, regional, multicenter registry. Circ Cardiovasc Interv
2010;3:593–601.
21. Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes
after primary angioplasty versus primary stenting with and without
abciximab for acute myocardial infarction: results of the Controlled
Abciximab and Device Investigation to Lower Late Angioplasty
Complications (CADILLAC) trial. Circulation 2005;111:1611–8.
22. Share DA, Campbell DA, Birkmeyer N, et al. How a regional
collaborative of hospitals and physicians in Michigan cut costs and
improved the quality of care. Health Aff (Millwood) 2011;30:636–45.KeyWords: peripheral arterial intervention - peripheral vascular disease -
sex.
APPENDIX
For an expanded Methods section and supplemental table, please see the
online version of this article.
